These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure. Shiga T; Matsuda N; Fuda Y; Haruta S; Hagiwara N; Kasanuki H J Cardiol; 2002 Mar; 39(3):159-64. PubMed ID: 11912950 [TBL] [Abstract][Full Text] [Related]
10. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. Amino M; Yoshioka K; Opthof T; Morita S; Uemura S; Tamura K; Fukushima T; Higami S; Otsuka H; Akieda K; Shima M; Fujibayashi D; Hashida T; Inokuchi S; Kodama I; Tanabe T J Cardiovasc Pharmacol; 2010 Apr; 55(4):391-8. PubMed ID: 20147846 [TBL] [Abstract][Full Text] [Related]
11. [Sotalol and torsades de pointes ventricular tachycardia]. Petersen HH; Sandøe E Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073 [TBL] [Abstract][Full Text] [Related]
12. Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone. Aiba T; Shimizu W; Inagaki M; Satomi K; Taguchi A; Kurita T; Suyama K; Aihara N; Sunagawa K; Kamakura S Pacing Clin Electrophysiol; 2004 Jul; 27(7):901-9. PubMed ID: 15271008 [TBL] [Abstract][Full Text] [Related]
13. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. Sen L; Cui G; Sakaguchi Y; Singh BN J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614 [TBL] [Abstract][Full Text] [Related]
14. The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation. Maeda K; Takagi M; Tatsumi H; Nakagawa E; Yoshiyama M Osaka City Med J; 2008 Jun; 54(1):11-9. PubMed ID: 18819261 [TBL] [Abstract][Full Text] [Related]
16. [Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function]. Murakami T; Makino Y; Kato H Kyobu Geka; 2007 Jun; 60(6):469-73. PubMed ID: 17564063 [TBL] [Abstract][Full Text] [Related]
17. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation. Wang J; Hua W; Zhu J; Yang YM; Wang FZ; Pu JL; Chen KP; Zhang S Chin Med J (Engl); 2010 Aug; 123(15):2028-33. PubMed ID: 20819537 [TBL] [Abstract][Full Text] [Related]
18. [Clinical experience with intravenous administration of nifekalant hydrochloride for ventricular tachycardia in a hemodialysis patient after open heart surgery]. Furukawa H; Aono H; Samukawa M; Iwasaki K; Ohkado A Kyobu Geka; 2010 Oct; 63(11):988-91. PubMed ID: 20954355 [TBL] [Abstract][Full Text] [Related]
19. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. Katoh T; Mitamura H; Matsuda N; Takano T; Ogawa S; Kasanuki H Circ J; 2005 Oct; 69(10):1237-43. PubMed ID: 16195624 [TBL] [Abstract][Full Text] [Related]
20. [Nifekalant hydrochloride as an effective treatment for postoperative ischemic heart disease]. Enomoto Y; Aoki K; Toshimitsu Y; Inai Y; Asakura T; Furuta S Kyobu Geka; 2005 Apr; 58(4):316-9. PubMed ID: 15828253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]